TROPION-Lung01 Study Design and Baseline demographics
Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as
First-Line (1L) Treatment for Unresectable Locally
Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC)
Updated Results From BEGONIA, a Phase 1b/2 Study
Professor Peter Schmid, FRCP, MD, PhD
Barts Cancer Institute, Queen Mary University of London, London, UK
P. J. Wysocki, C. X. Ma, Y. H. Park,³ R. Fernandes, 4 S. Lord, 5 R. D. Baird, 6 C. Prady,7 K. H. Jung, J. Asselah,9
R. Huisden, 10 R. Stewart, 10 K. Heider, 10 P. Vukovic, 10 N. Denduluri, 11 Z. Nowecki 12
1Jagiellonian University Medical College, Krakow, Poland; 2Washington University School of Medicine, St. Louis, MO, USA;
3Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 4Schulich School of Medicine & Dentistry, Western University, London Health Sciences Centre, London, Ontario, Canada; 5University of Oxford, Oxford, UK; 6Cancer
Research UK Cambridge Centre, Cambridge, UK; 7Sherbrooke University, Centre intégré de cancérologie de la Montérégie, CISSS Montérégie Centre, Greenfield Park, Quebec, Canada; 8Asan Medical Center - University of Ulsan, College of Medicine,
Seoul, Korea; McGill University Health Centre, Montreal, Québec, Canada; 10AstraZeneca, Cambridge, UK; 11AstraZeneca, Gaithersburg, MD, USA; 12Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Daiichi-Sankyo
36View entire presentation